AVIR
Atea Pharmaceuticals, Inc. Common StockstockNASDAQ
atea pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. the company's lead product candidate is at-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. it also develops at-787 which is under phase 2 clinical for the treatment of hepatitis c virus; at-752 which is under phase 2 clinical trial for the treatment of dengue; and at-889, at-934, and other product candidates for the treatment of respiratory syncytial virus are under phase 2 clinical trials. the company was incorporated in 2012 and is based in boston, massachusetts.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 4.20 | 2026-11-10 | -3.69% | 1.407 |
| 1M | 4.32 | 2026-10-16 | -6.37% | 1.496 |
| 3M | 5.22 | 2026-08-17 | -22.51% | 1.674 |
| 6M | 4.14 | 2026-05-18 | -2.29% | 1.095 |
| 1Y | 3.02 | 2025-11-17 | +33.94% | 0.868 |
| 2Y | 3.17 | 2024-11-18 | +27.60% | — |
| 5Y | 8.69 | 2021-11-17 | -53.45% | 1.023 |
Atea Pharmaceuticals, Inc. Common Stock (NASDAQ:AVIR) stock price today is $4.05, and today's volume is 20,068. AVIR is down 1.820% today. The 30 day average volume is 298,525. AVIR market cap is $324.83M with 80.30M shares outstanding.